BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis

HumanTERTpromoter mutation enables survival advantage fromMGMTpromoter methylation inIDH1wild-type primary glioblastoma treated by standard chemoradiotherapy

(2016) HuyTram N. Nguyen et al.   NEURO-ONCOLOGY

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

(2016) Hideyuki Arita et al.   Acta Neuropathologica Communications

A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation

(2015) Cheng-Ying Ho et al.   ACTA NEUROPATHOLOGICA

Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

(2015) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma

(2015) E. Tabouret et al.   EJSO

BRAFMutation andCDKN2ADeletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma

(2015) Matthew Mistry et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker-based prognostic stratification of young adult glioblastoma

(2015) Rui-qi Zhang et al.   Oncotarget

Combination genetic signature stratifies lower-grade gliomas better than histological grade

(2015) Aden Ka-Yin Chan et al.   Oncotarget

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences

(2015) Barbara Heidenreich et al.   Oncotarget

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

(2015) Patrick J. Killela et al.   Oncotarget

Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma

(2015) Chul-Kee Park et al.   Oncotarget

Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up

(2014) Cristiane M. Ida et al.   BRAIN PATHOLOGY

Analysis of KIAA1549–BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas

(2014) Gabriela Rampazzo Cruz et al.   JOURNAL OF NEURO-ONCOLOGY

BRAFV600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis

(2012) Carol Li et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

ToBRAFor Not toBRAF: Is That Even a Question Anymore?

(2012) Craig Horbinski   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

(2012) C. Horbinski et al.   NEURO-ONCOLOGY

The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

(2012) Gholamreza Safaee Ardekani et al.   PLoS One

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

(2011) Dora Dias-Santagata et al.   PLoS One

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE